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Abstract
Background: In 2010 the ‘Polymedication Check’ (PMC), a pharmacist-led medication review, was newly introduced to
be delivered independently from the prescriber and reimbursed by the Swiss health insurances. This study aimed at
evaluating the impact of this new cognitive service focusing on medicines use and patients’ adherence in everyday life.
Methods: This randomised controlled trial was conducted in 54 Swiss community pharmacies. Eligible patients used
≥4 prescribed medicines over >3 months. The intervention group received a PMC at study start (T-0) and after
28 weeks (T-28) while the control group received only a PMC at T-28.
Primary outcome measure was change in patients’ objective adherence, calculated as Medication Possession
Ratio (MPR) and Daily Polypharmacy Possession Ratio (DPPR), using refill data from the pharmacies and
patient information of dosing.
Subjective adherence was assessed as secondary outcome by self-report questionnaires (at T-0 and T-28) and
telephone interviews (at T-2 and T-16), where participants estimated their overall adherence on a scale from 0–100 %.
Results and discussion: A total of 450 patients were randomly allocated to intervention (N = 218, 48.4 %) and
control group (N = 232, 51.6 %). Dropout rate was fairly low and comparable for both groups (NInt = 37 (17.0 %),
NCont = 41 (17.7 %), p = 0.845). Main addressed drug-related problem (DRP) during PMC at T-0 was insufficient
adherence to at least one medicine (N = 69, 26.7 %). At T-28, 1020 chronic therapies fulfilled inclusion criteria for
MPR calculation, representing 293 of 372 patients (78.8 %). Mean MPR and adherence to polypharmacy (DPPR) for
both groups were equally high (MPRInt = 88.3, SD = 19.03; MPRCont = 87.5, SD = 20.75 (p = 0.811) and DPPRInt = 88.0,
SD = 13.31; DPPRCont = 87.5, SD = 20.75 (p = 0.906), respectively).
Mean absolute change of subjective adherence between T-0 and T-2 was +1.03 % in the intervention and
−0.41 % in the control group (p = 0.058). The number of patients reporting a change of their adherence of more
than ±5 points on a scale 0–100 % between T-0 and T-2 was significantly higher in the intervention group
(NImprovement = 30; NWorsening = 14) than in the control group (NImprovement = 20; NWorsening = 24; p = 0.028).
Conclusion: Through the PMC pharmacist were able to identify a significant number of DRPs. Participants
showed high baseline objective adherence of 87.5 %, providing little potential for improvement. Hence, no
significant increase of objective adherence was observed. However, regarding changes in subjective
adherence of more than ±5 % the PMC showed a positive effect.
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Background
Increasing complexity of both, the therapy (polyphar-
macy) and the patient (multimorbidity) raises the risk
for drug-related problems with adverse events and
medication errors [1, 2]. Avoidable problems usually do
not result from individual misconduct, but from subopti-
mal processes. Drug-related morbidity as a result of these
risks is associated with high healthcare costs [3–5].
Situations with a high risk for drug-related problems
(DRP) include polypharmacy, significant changes in drug
therapy or changes in existing diseases, insufficient re-
sponse to drug therapy, suspected lack of therapy, symp-
toms of side effects, as well as discharge from hospital
with a change of drug therapy [6, 7]. One approach to
reduce the risks for developing DRP is to conduct medica-
tion reviews [8–10]. A worldwide shift in the professional
role of pharmacists is observed [11]. Pharmacists partici-
pate increasingly in clinical processes and perform tasks
in patient care. This transformation of the profession in-
cludes co-responsibility in the achievement of therapeutic
success, cost efficiency and avoidance of drug-induced
(re)hospitalisation. Accordingly, the Pharmaceutical Care
Network Europe (PCNE) felt the need to redefine
pharmaceutical care as “the pharmacist's contribution to
the care of individuals in order to optimise medicines
use and improve health outcomes” [12]. In the early
1990s, pharmaceutical care was introduced in community
pharmacy practice in Switzerland. Emphasis was given to
providing patient-centred care and cognitive services [13].
A postgraduate education program and mandatory
continuous education were launched together with
changes to pharmacists’ remuneration, which link pay-
ments to services delivered and not only to the volumes of
medicines dispensed. In 2010, the current remuneration
system was introduced, which defines a fee schedule for a
total of nine distinct services. Among these services the so
called ‘Polymedication Check’ (PMC) was newly intro-
duced as the first cognitive service to be delivered by
pharmacists independently of the prescriber for patients
on ≥ 4 prescribed drugs taken over ≥ 3 months. In addition,
the pharmacist may suggest - among other interventions -
to provide the medicines in a weekly dosing aid (WDA)
refilled by the pharmacy. Both services, the PMC and
the weekly filling of a dosing aid by the pharmacist
are reimbursed by the health insurance in the basic
insurance. Moreover, the current regulation allows
repeated dispensing of prescribed medicines for a
maximum of 12 months. Currently, such prescriptions
constitute nearly 75 % of all items dispensed [14].
Hence, Swiss community pharmacies assume very
responsible roles in the care of chronic patients.
Adherence and consequences of non-adherence
Approximately 25 % of patients with different diseases do
not take their medication as prescribed, although the
extent varies between 0–95 % [15]. On average, adherence
in long-term therapy is 50 % [16]. Lack of adherence is the
most common cause of the efficacy-effectiveness gap [17],
defined as the gap between therapy efficacy in daily life
compared to the effectiveness shown in clinical trials.
Previous studies have shown a positive impact of
structured interventions to improve adherence provided
by pharmacists [18, 19]. But there is still little evidence
related to the effectiveness of interventions performed
in community pharmacies. A recent Cochrane review
revealed that only a minority of studies with lowest risk of
bias (RCT design) improved both adherence and clinical
outcomes [20]. However, adherence as an outcome re-
mains challenging to measure because of methodological
issues and multifactorial influences [21]. Support of
adherence to treatment is only successful if the entire
medication is taken into account. Therefore, conducting
a medication review is the essential first step in any
adherence counseling.
Medication review
According to the current PCNE definition, a medication
review is ‘an evaluation of a patient‘s medicines with the
aim of optimising medicines use and improving health
outcomes. This entails detecting drug-related problems
and recommending interventions.’ [22]. The analysis in a
medication review always includes an inventory of current
medicines, a history of complaints, their course, a patient’s
concerns and individual needs for support. With respect
to the pharmaceutical care process [12, 23], the medica-
tion review is the starting point leading to the suggestion
of solutions, the planning and implementation of inter-
ventions and ultimately to the evaluation of the outcomes
[24]. Pharmacist-led medication review services are avail-
able in several countries such as the United Kingdom
(Medicines Use Review, MUR) [25], United States of
America (Medication Therapy Management, MTM)
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[26, 27], Australia (Home Medication Review, HMR)
[28], Canada (MedsCheck) [29, 30], and New Zealand
(Medicines Use Review, MUR) [31]. According to a
recent meta-analysis, a majority (57.9 %) of fee-for-
service pharmacist-led medication reviews improved
medication adherence and positively influenced pa-
tient outcomes [24].
The Polymedication Check
The Swiss Polymedication Check (PMC) is based on the
well-established Medicines Use Review (MUR) from
United Kingdom [32, 33]. Information is available from
the medication history, which is mandatorily kept in
community pharmacies and from a structured patient
interview. The Swiss PMC focuses on adherence prob-
lems, patients’ knowledge and handling problems and is
followed by specific interventions or recommendations
by the pharmacist. Implementation of such cognitive
services provided by a pharmacist is known to be very
challenging [34–36]. The same is true for Swiss com-
munity pharmacies. Implementation of the PMC is
low and after three years only about three checks per
pharmacy per year were registered, with a large ma-
jority of pharmacies not offering this service. While
in 2011 2’534 PMCs were carried out, in 2014 the
number of PMCs provided amounted at 6'940 PMCs
[37], which is an encouraging trend.
Rationale for the study
In Switzerland, new services remunerated by the basic
health insurance require a proof of their efficacy, appro-
priateness, and economic effectiveness according
national criteria [38]. The present study aimed at investi-
gating the impact of the PMC on patients on poly-
pharmacy. It was hypothesised that PMC would increase
objective and subjective adherence in a community
sample.
Methods
Trial design
A prospective, parallel group randomised controlled trial
(RCT) design was chosen to evaluate the impact of
the PMC. Contemporaneously, an in-depth evaluation of
the process and the perspectives of patients and pharma-
cists was planned to collect information for further
development of the service. The study setting considered
community pharmacies in a range of representative
regions of Switzerland (with and without self-dispensing
physicians, city versus country, German-speaking part
(D-CH) versus French-speaking part of Switzerland
(F-CH)). For each patient the observation period lasted
28 weeks from study start (T-0) until study end (T-28).
Eligibility for study pharmacists
The recruitment of 70 pharmacists was intended; thus,
community pharmacies in the cantons Aargau (AG),
Basel-Land (BL), Basel-Stadt (BS), Solothurn (SO),
Fribourg (FR), Neuchâtel (NE), Genève (GE), Vaud (VD)
und Valais (VS) were invited to participate in the study.
Basing on the principle of "first in, first served", the ideal
recruiting target was 50 pharmacists from the German
speaking and 20 from the French speaking part of
Switzerland in line with the national proportion of the
population. Study pharmacists were required to take part
in a study-specific training, and to give written consent
regarding the study design as well as a memorandum of
understanding through the pharmacy owner to collabor-
ate on the project until the end of study; in addition,
they were asked to commit to transfer patient’s refill
data to the study centre, and to collaborate with ei-
ther IFAK or OFAC (the two main clearing compan-
ies in Switzerland administering the charges between
pharmacies and health insurance and therefore also
holding the corresponding patient data). The three-
hour training session provided by the study centre in-
cluded an overview over the study, highlighted the
need for compliance to the study protocol, and clari-
fied rights and responsibilities of the study pharma-
cists. No further training on the execution of a PMC
was offered as the study aimed at assessing and
evaluating current practice.
Screening for eligible patients
In order to avoid selection bias through study pharma-
cist (e.g. Individual prejudices, preferences), a random
sample of 100 potential PMC candidates (age >18, ≥4
prescribed drugs for ≥3 months) was created for each
study pharmacy in collaboration with the two main
clearing companies IFAK and OFAC. The latter per-
formed an independent screening for each study phar-
macy and listed all patients fulfilling the selection
criteria for a PMC. Out of this sample of potential PMC
candidates, a random primary sample of 100 was se-
lected by IFAK and OFAC (Fig. 1).
Patient recruitment
The study pharmacist checked this primary sample for
exclusion criteria and consecutively invited subsamples
of ten patients by a letter to participate in the study.
Exclusion criteria for final recruitment were the following:
living in a retirement home, prior PMC, receiving weekly
dosing aids filled by the pharmacy or another person,
cognitive impairment, move or death, insufficient know-
ledge of written and spoken German or French. In addition,
study pharmacists re-checked if a patient met the primary
inclusion criteria. The study centre received informa-
tion on gender, date of birth and the reasons for
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exclusion of a patient. If the patient had expressed
his interest in the participation, the study pharmacist
informed him about the schedule, potential risks, and
compensation and handed over the declaration of
consent.
Randomisation process
The patients were assigned by 2 x 4 block randomisation
into intervention or control group. Initially, each study
pharmacist received two blocks containing eight dos-
siers (four intervention and four control) each packed
in sealed and unlabelled envelopes. Once the first
patient had consented, the study pharmacist opened
one envelope out of the first block to reveal what
arm of the study the patient had been randomised to.
Once all eight envelopes of block No. 1 had been
assigned, the next block was used. Upon request, fur-
ther blocks were available.
Structure of the intervention vs usual care
The intervention at T-0 included the execution of a
PMC according to the official guidelines. The adapted
study PMC protocol was used as assessment form. In a
structured face-to-face counselling with the patient, the
Fig. 1 Study flow chart with screening and recruitment process
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study pharmacists screened all medicines currently used.
The pharmacists checked for any gaps in knowledge or
other pharmaceutical care issues including handling and
adherence problems. The interview took place in a sepa-
rated area. Pharmacists were instructed to use open
questions to detect pharmaceutical care issues and to
decide if there was need for further investigation. For
each medication, the PMC protocol (Additional file 1)
required documentation whether the patient knew the
reason why he/she took the medicines (yes/no), if he/she
needed any counselling (yes/no) or had adherence prob-
lems (yes/no). Additionally, handling difficulties were
enquired, and the pharmacist documented all resulting
interventions such as consultation with the general prac-
titioner (GP), referral of the patient, potential suggestion
and implementation of a weekly dose reminder system,
or any other recommendations or interventions. Where
necessary, an individual patient education and a medica-
tion plan could be provided on the basis of the informa-
tion gained from the interview. None of this follow-up
interventions was standardised.
Usual care included no specific intervention and no
documentation at T-0. Patients of the control group only
received the two self-report questionnaires at study start
and study end, and the two telephone interviews.
Normal counseling for any new prescription or arising
question from the patient was always allowed and guar-
anteed, so patients from this arm were not restricted
from contacting the pharmacist for advice if they wished
to do so. If a PMC became indispensable during the
study period (e.g. by another pharmacist than the study
pharmacist), this patient of the control group was ex-
cluded. Overall, the study took seven months for each
patient and included two visits at the pharmacy with the
completion of questionnaires and participation in two
telephone interviews. Patients were able to contact the
study centre in case of further interest for the study pur-
poses or any problem with the study process (e.g. missed
telephone interview) using a separate telephone hotline
available 24 h seven days a week.
Classification of detected drug-related problems and
addressed interventions
To classify the addressed drug-related problems and
describe the pharmacists’ interventions, the GSASA
classification tool was used [39] This instrument com-
prises five main categories: i) problem, ii) type of prob-
lem, iii) cause, iv) intervention, and v) outcome. We
adapted the category ‘causes’ by dividing the section
‘Insufficient knowledge of the patient’ into three subdo-
mains focussing on patients’ individual needs for infor-
mation about a) safe and effective use of his medicines
b) the medicines’ potential adverse drug reactions c) his
lifestyle, nutrition or empowerment in general. Further
on, we added the category ‘More cost-effective therapy
available’ as the recommendation of generic drugs might
be likely triggered throughout a PMC.
Case report forms for study pharmacists
In order to support study pharmacists in their compli-
ance to the study protocol and to ensure coherent data
capture, case report forms (CRF) were developed. The
study pharmacist documented his interventions or rec-
ommendations resulting from PMC, classified the
underlying problems according to their urgency (low,
medium, high urgency) added any abnormalities or
changes in the care of the patient.
PMC protocol form
We used the official documentation form for PMC with
minor changes to ease data capture for the purpose of
the study (Additional file 1). This assessment form still
showed the format of one A4 side. At study end (T-28),
in addition to the PMC protocol the study pharmacist
documented observed drug-related problems, the fre-
quency of falls, and all changes in therapies since T-0
reported by the patient (dosage change, generic substitu-
tion, start/stop, no change). The documentation of these
changes was needed to identify eligible therapies for
objective adherence calculation.
Patient self-report questionnaires
Patient self-report questionnaires were developed to
collect demographic data (age, gender, living situation,
education and employment status, smoking status), but
also to describe his limitations in executing everyday
activities (four items extracted form of the Disabilities
of the Arm, Shoulder and Hand (DASH) questionnaire
[40]) and assess his subjective adherence at T-0 and
T-28. The patient therefore had to assess his adherence
to all his prescribed medicines for the last two weeks
using a visual analogue scale (VASAD) 0–100 mm repre-
senting 0 for ‘taken none’ and 100 for ‘taken all my med-
icines’. Patients were asked to fill in the questionnaires
in the pharmacy at T-0 and T-28, seal them in an enve-
lope and return the envelope to the study pharmacist.
Thus, the study pharmacists had no knowledge of the
responses given by their patients.
Telephone interviews
In collaboration with a clinical psychologist and an
economist, two comprehensive in-depth patient tele-
phone interviews were developed aiming at monitoring
possible impact of the intervention on patient’s know-
ledge and medicines use. After literature research, the
Rob Horne’s ‘Beliefs about Medicines Questionnaire’
[41] and two questions out of the ‘8-item Morisky Medi-
cation Adherence Scale’ (German version, 8-MMAS-D)
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[42] were defined as suitable to be used as validated
questionnaires fulfilling our criteria for telephone inter-
view 1. In addition, we developed new rating questions
to report their adherence to their therapy management.
Patient had to answer the same question as in the pa-
tient questionnaire T-0 to describe their adherence, but
in a spoken percentage value. We also chose consistently
a 10-item Likert scale. Options ranged from 1 (= ‘not at
all’) to 10 (= ‘very much’). The response category ‘no an-
swer’ was always available. Number of open questions
(N = 7) was limited to ease documentation.
The first telephone interview contained 58 questions,
divided into five sections: i) knowledge of their medi-
cines and daily use, ii) subjective adherence estimation/
use of reminder devices, iii) visits at general practi-
tioner/hospital, iv) beliefs about medicines question-
naire, v) support by pharmacists. The interview 2
contained 53 questions, divided into the same sections
as in the first interview. Compared with the first inter-
view, 18 questions were excluded and 13 new questions
were added. The telephone interviews were carried out
two (T-2) and 16 weeks (T-16) after study start by clin-
ical psychologists. The interviewers were blinded to the
intervention and without any knowledge of the content
of the PMC or the patient’s questionnaire T-0. A tele-
phone interviewer’s coaching and monitoring of compli-
ance with the study protocol was continuously provided
by an independent academic psychologist as external ex-
pert. A structured interview guide was created using the
software program Flexiform 2.6.9 to enable data entry
during the interview. Piloting of all study documents
and preparation of telephone interviews (recruiting in-
terviewers, briefing and test interviews) were carried out
in collaboration with the department of psychology of
the University of Basel. All survey instruments were
translated into French and retranslated into German to
check for differences.
Objective adherence measurement
Objective adherence rates based on refill data of the
pharmacies and patient reported dosing regimen. Two
methods for objective adherence calculation were used:
a) Medication Possession Ratio (MPR) [43], calculated
by dividing the days’ supply of a medication dispensed
by the number of days in the time interval of interest,
representing the adherence per each medicine and b)
Daily Polypharmacy Possession Ratio (DPPR) [44], the
proportion of time a patient had medication available for
use by considering the presence or absence of multiple
medications on each day in the observation period,
representing the adherence per patient with his chronic
polypharmacy. In this analysis only medicines were in-
cluded, of which the patient reported at T-28 a daily use
over the whole study period. Only oral drug forms with
definite dosage where considered. Further, a prescription
for the medicine had to be redeemed at least once before
T-0. Therapies were excluded if prescribed by self-
dispensing physicians (cantons BL/SO), changed in dos-
age during study period, chronic ‘on demand therapies’
(namely pain killers (ATC N02 and M01A), anxiolytics
(ATC N05BA), or magnesium supplements (ATC
A12CC). Also creams or drops where excluded from
analysis due to imprecise assumption concerning dosing
regimen. According to the theoretical calculation for
both, the MPR and the DPPR, refill data was exported
from the patient’s pharmacy. The export included the
history of patient’s refills from at least 200 days before
T-0 and the study period (T0 to T28, 196 days). For each
dispensed medicine, the export comprised the date of re-
fill, a product unique identifier number (pharmacode),
the drugs’ATC-Code, and the number of packages deliv-
ered. Subsequently, the pharmacode was matched with
the Swiss index database GALDAT®/pharmINDEX® [45]
to add the products’ package size (number of tablets)
and complemented with the patient reported dosing
regimen at T-28 (taken from the PMC protocol of both,
intervention and control group). The calculation algo-
rithm started with a look-back loop of 200 days before
T-0 taking any packages of medicines postponed to the
patient, equalising the fact that the patient was already
on therapy before study start. As in previous trials, ob-
jective non-adherence was defined as MPR <80 % [46].
Also for the patient’s individualised aggregated measure
DPPR, the cut-off for non-adherence was set <80 %.
Subjective adherence measurement
Subjective non-adherence was defined in patient re-
ported questionnaires (T-0 and T-28) as VASAD <100 m,
in telephone interview 1 and 2 as Likert scale <10 and in
telephone interview 2 additionally as 8-MMAS-D <6.00.
Unplanned visits at the general practitioner/hospital
In order to evaluate a negative impact on the health sys-
tem, patients’ unplanned visits at the general practitioner
or hospital were assessed within the patient’ self-report
at T-0 and T-28 and during telephone interview at
T-2 and T-16.
Sample size
To determine the required sample size, a power analysis
was conducted. In the present study, the null hypothesis
is rejected if the primary outcome adherence (as mea-
sured by MPR) improves by 5 % through the PMC on an
assumed baseline MPR of 60 %. These suggestions were
based on experiences from comparable projects [47].
We assumed a standard deviation of 20 % for both
groups and used the conventional alpha error of 5 %. To
have a statistical power of 80 % we would require 252
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patients at T-28 in each group. Assuming a dropout
rate of 35 % [48], this would lead to a total sample
size of 780 at T-0 (calculated with http://sampsize.-
sourceforge.net). Thus, we expected from each study
pharmacists an enrolment of 10–20 patients. There
was no minimal/maximal number for recruited pa-
tients per study pharmacist.
Statistical methods
Frequencies were evaluated using the chi-square test, or-
dinal scales were tested with the non-parametrical
Mann-Whitney-U-test. The time course of the various
endpoints was calculated using a general linear model
(GLM) for repeated measurement method. The study
groups were recorded as between-subject variable and
the course of the corresponding values as within-subject
variable in the model. In case of many missing values,
individual templates mixed models analysis was chosen
as an alternative method. All statistical tests were two-
sided with a significance level of 5 %.
Handling missing data
The intention-to-treat analysis included all enrolled sub-
jects, divided into intervention and control groups. Pa-
tients were rated as a drop out when they were excluded
at their request or when they were no longer available at
study end. Reasons for drop out were documented if
available. Patients who missed one or both telephone in-
terviews remained in the study.
Ethical approval
The study was approved by the responsible local ethic
commission ‘Ethikkommission beider Basel (EKBB)’
(23.05.2012, registry number EKBB 50/12) as the leading
committee for this multicentre study. Following the
positive decision from the EKBB, the project was also
approved by the local ethics committees of the following
cantons: AG/SO (26.11.2012), VS (05.03.2013), VD/NE
(12.03.2013), GE (22.03.2013), and FR (25.03.2013). The
study was registered with the https://clinicaltrials.gov/
trials database (NCT 01739816). The fee for providing
the PMC was covered by basic health care insurance.
Study pharmacists received a compensation of CHF 150
for participating in the training session and CHF 50 for
the delivery of each complete patient data set. Patients
were paid CHF 20 for their time spent for the telephone
interviews, and as a compensation for obligatory co-
payment to the PMC-fee.
Results
Implementation of the study
Patient recruitment was conducted in three stages (BS,
BL: July 2012 – February 2013, AG, SO: December 2012
– July 2013, the French speaking cantons (VS, VD, NE,
GE, and FR): April 2013 – October 2013) and ended in
April 2014 with the last patient completing the study
protocol.
Recruitment of study pharmacists and study pharmacies
Of 413 pharmacies invited for participation (NBS/BL =
110; NAG/SO = 135; NVS/VD/NE/GE/FR = 168), 70 pharma-
cists signed the informed consent and were trained to
follow the study protocol. In the end, 64 pharmacists
(91.4 %) from 54 different pharmacies took part in the
study (Table 1). Pharmacies were more or less evenly
distributed between central (N = 15, 27.8 %), peripheral
(N = 16, 29.6 %) and urban settings (N = 23, 42.6 %) as
well as between being independent (N = 17, 31.5 %), be-
longing to a group (N = 23, 42.6 %), and belonging to a
chain (N = 14, 25.9 %). A majority of 75 % of study phar-
macists were women (N = 48), mean age was 42.8 years
(SD 11.61), mean professional experiences working in a
community pharmacy was 14.9 years (SD 10.69), and 27
pharmacists (42.2 %) had post graduate qualification in
community pharmacy. The pharmacies showed variation
in both size and infrastructure. Virtually all pharmacies
were well equipped with a private area for the patients
in terms of ensuring privacy from other patients (N = 51,
94.4 %). The median consulting area was 7 square me-
ters (Range 1-25 m2).
Patient recruitment
For each pharmacy a random sample of potential candi-
dates was delivered directly to the study pharmacist by
Table 1 Demographics of study population at T-0, divided in language regions German-speaking (D-CH) and French-speaking
(F-CH) part of Switzerland. The total sum per study group is highlighted in bold
Intervention group (N = 218) Control group (N = 232)
D-CH (n = 146) F-CH (n = 72) Sum D-CH (n = 160) F-CH (n = 72) Sum pValue
Women (n/%) 76 52.1 42 58.3 118 54.1 78 48.8 47 65.3 125 53.9 0.958
Living alone (n/%) 53 36.3 25 34.7 78 36.5 42 26.3 31 43.1 73 31.9 0.310
Smoker (n/%) 20 13.7 19 26.4 39 18.5 27 16.9 7 9.7 34 15.0 0.335
Age in years (Mean/SD) 66.4 11.38 68.7 11.73 67.2 11.52 67.1 10.80 67.2 13.18 67.1 11.56 0.845
Dash-4 score (Mean/SD) 4.7 1.72 5.3 2.43 4.9 2.01 4.7 1.48 5.3 2.40 4.9 1.83 0.323
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IFAC and OFAC. The study pharmacists then consecu-
tively checked samples of ten candidates for inclusion
and exclusion criteria and invited the eligible patients.
Exclusion criteria are available for 3096 patients as re-
ported by 49 pharmacists (76.6 %) (Fig. 2). The other 15
pharmacists did not report about exclusions. After invi-
tation, a total of 450 patients signed the IC and were
randomly allocated to intervention (N = 218, 48.4 %) and
control group (N = 232, 51.6 %) (Fig. 3). Median number
of recruited patients per pharmacist was 7 (Range 1–17).
Demographic data of recruited patients
Demographic data of recruited patients (N = 450)
showed no significant differences between study groups
(Table 1). The proportion of women living alone (111
of 243) compared to men (40 of 207) was significantly
higher (p < 0.0001). Men showed a significantly lower
DASH-4 score than women (MenDASH-4 = 4.5 (SD 2.09),
WomenDASH-4 = 5.2 (SD 1.60); p < 0.0001). No differ-
ences between groups observed concerning education
and employment (data not shown).
Dropouts
Out of 70 study pharmacists, six (8.6 %) withdrew before
recruiting any patient for the study. While four stated
that they had under-estimated the time amount to com-
ply with the study protocol, two were no longer inter-
ested in the project. Dropout rate of patients was 17.3 %
(N = 78); the different reasons for dropout are listed in
table 2. Only 18 patients (4.0 %) withdrew from the
study. The largest single cause for dropout of patients
was that five of the 64 pharmacists who began recruiting
quit the study (7.8 %), resulting in 17 patients lost in
each group.
Intervention
Mean time per PMC was 29.8 min (SD 16.51; Range 5–
135 Min). Mean number of chronic medication per pa-
tient was 6.8 (SD 2.92; Range 1–19), while 1.9 medicines
(SD 2.07; Range 0–12) were prescribed on demand and
0.8 medicines (SD1.09; Range 0–5) were used as self-
medication. A majority (N = 115, 52.8 %) revealed to be
more time consuming than initial assumptions of the
professional association, pharmaSuisse (>25 min). At T-
0, study pharmacists reported 258 drug-related problems
(1.18 per patient) they had discussed during the PMC.
The two main causes of drug-related problems triggering
counseling through study pharmacists were a) insuffi-
cient adherence to at least one medication of a patient’s
polypharmacy (N = 69, 26.7 %) and b) lack of knowledge
about risks or need for further information for safe and
effective medicines use (N = 69, 26.7 %). The majority of
DRPs could be addressed by sole patient counseling
(58.9 %). Some pharmacists, however, also intervened by
directly changing a patient’s care plan in order to opti-
mise the administration of a therapy (15.5 %), adjust the
dosage or substitute a therapy (3.9 %) (Table 3). Study
pharmacists noted at T-0, that 69 patients in the inter-
vention group (31.5 %) already used a weekly dosing aid
(WDA) in their daily medicines management and they
recommended the implementation of a WDA for three
patients (1.4 %) (Table 4). During the first telephone
interview at T-2, 198 patients stated to own a WDA
(47.6 %); 173 of them regularly used the aid (41.6 %),
while seventeen patients mentioned a sometime use, e.g.
during holidays (4.1 %); eight patients did not use the
WDA at all (1.9 %). Until the end of the PMC study
(T-28), one patient in the intervention group (0.6 %)
and four patients of the control group (2.1 %) newly
received a WDA as a result of the PMC. When asked at
T-2, 74 (42.8 %) of 173 patients, who had originally been
Fig. 2 Pattern of reasons for exclusion after screening the random sample of potential candidates (N = 3096)
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recommended to use a dosing aid, reported that the phar-
macy initiated the use of a WDA. Another 54 (31.2 %)
bought the WDA themselves, while 20 (11.6 %) received
the aid from a hospital. Out of these 173 WDA used
at T-2, 158 were independently managed by the patient
himself (91.4 %), get refilled by their partner (N = 13,
7.5 %) or another third party (N = 2; 1.1 %). Thereby,
men (N = 77) were significantly more often supported
by their partners (N = 12) than vice versa (NWomen =
94, NSupport = 1; p < 0.001).
Objective adherence
Out of 2’453 chronic therapies registered in the PMC
protocol at T-28, 1’020 (41.6 %) met inclusion criteria
for the calculation of their Medication Possession Ratio
(MPR) using the defined algorithm (Additional file 2).
Sub-analysis of therapies inert to dose adjustments or
splitting (and therefore with highest expected validity for
calculation of MPR) showed consistent, but no signifi-
cant trend for improved adherence rates in the interven-
tion group (Table 5). For 212 out of 1'020 therapies
(20.8 %) the MPR was < 80 % (intervention N = 96
(19.5 %) and control group N = 116 (22.0 %), p = 0.318).
Out of all therapies, the Daily Polypharmacy Possession
Ratio (DPPR) was calculated for each individual patient as
shown in Table 6 (Additional file 3). Mean DPPR over the
whole eligible study population was 87.3 (N = 293, SD =
14.250). In both, intervention and control group, the DPPR
in D-CH (mean = 88.38, SD = 14.270) was significantly
higher compared to that of F-CH (mean = 84.86, SD =
13.972) (p = 0.01). Both regions showed no significant
improvement of DPPR through the intervention (Fig. 4).
Subjective adherence
In addition to objective adherence, we asked participants
how they estimated their overall adherence on a scale
from 0 to 100 %. The mean absolute change of subject-
ive adherence between T-0 and T-2 was +1.03 % in the
intervention and −0.41 % in the control group (p =
0.058) (Table 7). Sub-analysis revealed, that the number
Table 2 Reasons for patient dropout summed at T-28, N = 78
Intervention Control pValue
Deceased 2 2
Withdrawal by patient
- without information 5 7
- lack of motivation/interest 1 1
- poor health 0 4
Pharmacist was unable to
collect data
- not achieved 5 5
- patient has moved away 3 2
- patient is in a nursing home 2 0
- poor health 2 3
Lost because pharmacist
revoke study participation
17 17
Total n (%) 37 (47.4) 41 (52.6) 0.845
Fig. 3 Recruited pharmacists and patients (D-CH = BS/BL/AG/SO, F-CH = GE/FR/NE/VD/VS)
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of patients reporting a change of their adherence of
more than ±5 points on a scale 0-100 % between T-0
and T-2 was significantly higher in the intervention
group (NImprovement = 30; NWorsening = 14) compared to
the control group (NImprovement = 20; NWorsening = 24) (p
= 0.028). Table 8 summarises patient self-report of
adherence using validated questionnaires. Between the
two telephone interviews T-2 and T-16, mean difference
between patients’ beliefs and concerns about their
medicines did not change significantly (Intervention =
−0.01 (SD 6.609); Control = +0.64, (SD 6.289), p = 0.697).
At T-16, in total 74 patients had a MMAS-8D score <6
representing low adherence (intervention N = 37 (18.9 %),
control N = 37 (18.3 %)). Moderate adherence (Scores 6–8)
was shown in the intervention group for 83 patients
(20.8 %) and in the control group for 89 cases (22.3 %).
High adherence was present in 154 patients, 78 from the
intervention (39.4 %) and 76 from the control group
(37.6 %). No significant difference in adherence between
the two groups could be observed (p = 0.817).
Use of health care resources by patients and unplanned
visits at a general practitioner or hospital
According to the notations in the CRF in 18 cases
(8.3 %) out of the 258 DRPs addressed at T-0, the study
pharmacist contacted the responsible general practi-
tioner (N = 17) or an indicated specialist (N = 1) to dis-
cuss or inform about issues revealed through the PMC.
A phone call was reported in six cases (33.3 %), the
other issues were addressed by Fax (N = 5, 27.8 %), Email
(N = 1, 5.6 %), referral letter (N = 1, 5.6), otherwise (N =
3, 16.7 %), not specified (N = 2, 11.1 %). Four out of 18
physicians did not respond to the pharmacists’ initiative
(22.2 %). The remaining 14 (77.8 %) gave feedback on
Table 3 Drug-related problems addressed during PMC at T-0 in
intervention group (N = 258)
N %
Drug-related problems
Potential 149 58
Manifest 109 42
Urgency rated by the study pharmacist
High 36 14
Medium 113 43
Low 109 43
Recommendation accepted by patient
Yes 219 85
No 25 10
Unclear 14 5
Causes of pharmacists’ interventions
Insufficient adherence 69 26.7
Patient needs information about safe and
effective use of his medicines
50 19.4
Patient needs information about potential
medicines’ adverse drug reaction
19 7.4
Inappropriate timing or frequency of
administration
18 7.0
Under-dosed therapy 15 5.8
Drug-drug/drug-food interaction 14 5.4
Adverse effect 12 4.7
Inappropriate therapy duration 10 3.9
Inappropriate drug administration 9 3.5
Patient needs information about lifestyle,
nutrition or empowerment
8 3.1
Not received treatment 7 2.7
More cost-effective therapy available 5 1.9
No concordance with guidelines or
contraindication
4 1.6
No dose adjustment because of
pathological changes (renal/liver failure)
4 1.6
Not indicated drug or duplication 3 1.2
Incomplete patient documentation 3 1.2
Over-dosed therapy 3 1.2
Prescribed drug not available 2 0.8
Inappropriate monitoring 1 0.4
Not classifiable 2 0.8
Description of pharmacist's interventions
Counseling of patient, training 152 58.9
Optimisation of administration 40 15.5
Information to other caregivers 24 9.3
Dose adjustment 12 4.7
Substitution of a therapy 10 3.9
Table 3 Drug-related problems addressed during PMC at T-0 in
intervention group (N = 258) (Continued)
Therapy started/restarted 7 2.7
Therapy stopped 7 2.7
Therapy monitoring 3 1.2
Clarification in the patient history 2 0.8
Not classifiable 1 0.4
Table 4 Overview of weekly dosing aids in use during study
Intervention Control pValue
T-0 (assessed through pharmacist
during PMC)
72a N = 218 - -
T-2 (assessed through telephone
interview)
83 N = 202 90 N = 214 0.838
T-16 (assessed through telephone
interview)
90 N = 198 98 N = 203 0.699
aFrom which three were newly implemented through PMC
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the addressed issues. Nine fully accepted the pharma-
cists’ recommendations (64.3 %), one partially (7.1 %),
and two rejected the recommended intervention
(14.3 %). In two cases, the implementation of the recom-
mendations remained unclear (14.3 %). During the study
period, patients reported a total of 209 unplanned visits
at a general physician or hospital, showing no significant
difference between study groups (Table 9). The same
was observed for the incidence of falls during the study.
Discussion
Our study presents initial findings on a newly imple-
mented pharmacist-led medication review service, called
Polymedication Check (PMC) with respect to impact on
patients’ adherence. The multicentre parallel group ran-
domised controlled trial was conducted in community
pharmacies with very low to moderate experiences in
providing medication reviews. This paper presents re-
sults from multiple in-depth assessments focusing on pa-
tients’ adherence and drug-related problems; humanistic
outcomes and the patients’ as well as pharmacists’ per-
spectives will be dealt with in a second publication.
Study population
Recruitment of study pharmacists posed no problem; all
recruited pharmacists attended the required training ses-
sion. However, experience with providing a PMC proved
to be unequal with only 28 % of pharmacists featuring
prior experience in conducting >5 PMC and even 34 %
with no prior experience at all. Nevertheless, a majority
of the study pharmacists who finally started to enrol pa-
tients in the project was highly motivated to participate
in this evaluation study despite the complexity of the
study protocol and their lack of experience with partici-
pation in randomised controlled trials. In all regions a
suitable sample of pharmacies was involved into the
study. The demographics and characteristics of the par-
ticipating pharmacies were in line with the total of Swiss
pharmacies regarding organisational form of ownership
and gender compared to RoKA report 2012 [49] (per-
sonal ownership and group (study: 74.1 % vs. RoKA:
69.6 %) or chain (25.9 % vs. 30.4 %), women (75.0 % vs.
80.0 %)). The estimated number of ten patients recruited
by each study pharmacist was not reached by most phar-
macists (Median 7; Range 1–17) despite up to six
months of recruitment period per study region. During
the study, six study pharmacies cancelled participation
before they started recruiting patients and five more
dropped out during the study; as a consequence follow-
up of their patients was impossible. Patient dropouts
were fairly low (17.3 %), evenly distributed across both
study groups and caused by an expected pattern of com-
prehensible reasons, so there is little concern for a selec-
tion bias due to selective dropouts. The reported causes
were both rare and typical, such as patients’ moving
away or being unable to continue due to health reasons.
Impact of the Polymedication Check
The primary outcome objective adherence showed no
significant improvement in the PMC group (mean MPR
88.3 % vs 87.5 % in the control group (p = 0.811)).
The adherence in the control population was already
at an unexpectedly high rate of 87.5 %, leaving only little
room for improvement in the intervention group. This
made it nearly impossible to observe the 5 % increase in
objective adherence, on which the power calculation was
based. Notably, in the intervention group a higher per-
centage of patients showed more than 5 % increase of
subjective adherence compared to the controls. This
effect only appeared shortly after the intervention and
could not be observed again in the further course of
the study.
Our results show that during the PMC non-adherence
to medication was the most frequent issue addressed in
26.7 % of PMC cases, followed by a need for information
about safe and effective medicines use (19.4 %) or im-
provement of awareness for risks and adverse effects of
therapies (7.4 %). Previous research has shown that
adherence counseling was included in only 6.7 % of the
reported cases of unspecific pharmacist-patient contacts
Table 5 Objective adherence represented as MPR
Intervention Control
Mean % SD N Mean % SD N pValue
All therapies 88.3 19.03 493 87.5 20.75 527 0.811
Antiplatelets (B01AC) 91.3 16.24 61 85.4 23.75 64 0.119
Proton pump inhibitors (A02BC) 91.8 13.36 43 87.7 18.27 33 0.493
Table 6 Objective adherence to polypharmacy represented as
DPPR over all patients (N = 293)
Intervention
(N = 146)
Control
(N = 147)
Mean SD Mean SD pValue
DPPR (%) 88.0 13.31 87.5 20.75 0.906
Number of medicines eligible for
DPPR calculation per patient
3.4 1.68 3.6 1.86 0.425
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in usual care [14]. This pattern of detected and discussed
drug-related provides an important indication on the
impact of the PMC and proves appropriateness of the
concept of the PMC regarding its aim at triggering ad-
herence and knowledge issues as topics for individual
counseling. The filling of a patient’s medicines into a
WDA could be implemented in only very few patients
(1.4 %). This unexpected result can be explained with a)
the pharmacist judged the patient sufficiently well-
organised without a WDA, b) the patient already used a
WDA in self-management (which was the case in 42 %
of patients in our study) or c) the patients were not will-
ing to delegate the preparation of their medicines to the
pharmacist. There is a necessity for guiding a compre-
hensive assessment of patient needs (self-management of
a WDS versus WDA provided by the pharmacy) and
differentiating between the active recommendation by
the pharmacists and the refusal by the patient. The im-
plementation rate of WDA in patients with chronic
polypharmacy revealed in our study, still offers room for
improvement; recent surveys in Canada could show that
75 % of patients in a comparable community sample
stated to regularly use a WDA [50]. With respect to the
interface between pharmacy and GP, 18 out of the 258
cases of detected and addressed DRPs in the PMC group
at T-0, cases triggered a consultation with the patient’s
GP (7.0 %), leading in 77.8 % to an interprofessional col-
laboration and discussion of patients’ DRP with high
acceptance rate of pharmacists’ recommendations
(71.4 %). Still, considering the recommendations without
feedback or acceptance by the GP (N = 8), the overall
implementation rate of 44.4 % is comparable to a study
of Kempen et al. [51], who reported implementation
rates of 42 %. Such low implementation of recommenda-
tions will decrease efficacy of any intervention substan-
tially. However, it can be deduced that the pharmacists
were able to solve more than 90 % of the patients’ issues
independently.
Unlike reported in previous studies [52], no harmful
effect of the PMC intervention as reflected by the non-
significant group differences in unplanned hospital ad-
missions or in visits to the GP (Table 9) could be ob-
served. This observation is meaningful when looking at
the frequency of contacts of pharmacists with the pre-
scriber resulting from a PMC (8.3 %) and considering
that only a few of the pharmacists’ recommendations
(14.3 %) were rejected. A significant number of DRPs
were discovered and solved through study pharmacists
providing a PMC (Table 3).
Reasons why we did not detect a significant effect
Overall, the study remained underpowered: The initial
estimation of the impact on adherence of the PMC was
set on 5 % with a baseline at around 60 %. This assump-
tion was based on the results of other studies from
different countries and settings [47]. The unexpected
high adherence observed in the control group allowed
only little improvement. Thus, a sole increase of the
study population, e.g. through an extension of the re-
cruitment period, would remain ineffective. A more
effective and internationally accepted approach to
enhance the efficacy of medication reviews would be the
targeting of patients at risk [9]. The high rate of imple-
mented WDA at T-2 (42 %) (Table 4) indicates an already
Fig. 4 Box plot of DPPR of patients stratified by the German (D-CH,
N = 199) and the French part of Switzerland (F-CH, N = 94)
Table 7 Subjective rating of adherence during the preceding two weeks
Intervention Control
Mean % SD N Mean % SD N pValue
Patient questionnaire T-0 96.2 8.62 211 96.8 7.05 232 0.204
Telephone interview T-2 97.2 9.31 202 96.4 10.24 213 0.118
Telephone interview T-16 98.5 5.56 198 97.8 7.64 202 0.400
Patient questionnaire T-28 95.5 10.28 178 96.3 9.51 186 0.338
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improved patient’s self-management mostly initiated
through pharmacists before study start. It was a deliberate
decision not to focus on patients with specific diseases or
drugs in this first evaluation since the service might be
offered to every patient meeting the inclusion criteria for a
PMC. Since the inclusion criteria were non-specific in
terms of risks for non-adherence, it must be assumed, that
already well-organised patients with established therapies
were included in this study. Further on, patients with the
highest need for intervention with manifest non-
adherence might not have been motivated to be part of a
clinical trial that explicitly aimed at uncovering indi-
vidual weaknesses in the correct administration of
medicines. Experiences with the MUR service from
UK resulted in the development of specific interven-
tions for various patient populations, offering to the
health care provider a structured and focused flow
chart supporting the process of screening for pharma-
ceutical care issues [53]. Thus, applying more specific
criteria in addressing the medication reviews to patients
with higher risk for drug-related problems would probably
increase the impact of the intervention.
Medication reviews such as the PMC are a screening
method aiming at detecting drug-related problems, and
the corresponding interventions are unspecific. Thus,
in a first step, this service only results in a number of
drug-related problems detected or number of referrals
etc. Looking at clinical outcomes, only well planned
and monitored interventions can have an impact. The
current PMC protocol specifies the provision of a
weekly dosing system filled by the pharmacy as its main
intervention. This intervention, though known to be
effective [54], was offered only to very few patients
(1.4 %). All other interventions such as delivery of a
medication plan or check of correct use of an asthma
device are not foreseen in the protocol and hence
could not been evaluated. On the other hand, explicit
listing of such predefined interventions on the
protocol would probably trigger more frequent
provision of such services. So far, the intervention
part is insufficiently specified in the current guideline,
and especially not well supported by the current
PMC protocol.
Strengths
First, the randomised controlled trial design is a distinct
strength of this study. Second, the trial was performed
under real-life conditions with a representative sample
of pharmacists from different regions, including the
French-speaking part of Switzerland with differences
related to health care (i.e. density of pharmacies,
Table 8 Summed scores of validated adherence questionnaires at T-2 and T-16
Intervention Control
Mean SD N Mean SD N pValue
T-2
BMQ Beliefs 20.58 4.463 171 20.99 4.301 181 0.328
BMQ Concerns 9.95 4.249 171 10.30 4.949 181 0.726
Difference Beliefs - Concerns 10.64 5.554 171 10.69 6.494 181 0.612
T-16
BMQ Beliefs 20.66 4.630 188 21.23 3.958 183 0.369
BMQ Concerns 9.89 5.020 188 9.72 4.583 183 0.872
Difference Beliefs - Concerns 10.77 6.360 188 11.51 5.705 183 0.337
MMAS-8D Scorea 6.85 1.226 198 6.82 1.237 202 0.817
aMMAS-8D Score: 8 = high adherence, 6–7.75 medium adherence, <6 low adherence
Table 9 Patient reported unplanned visits at general practitioner or hospital and falls during study period
Intervention Control
Unplanned visits … NYES NTotal NYES NTotal pValue
… from T-0 - > T-2 14 202 10 214 0.324
… from T-2 - > T-16 50 198 44 203 0.398
… from T-16 - > T-28 46 181 45 191 0.678
Incidence of at least one fall until T-28 31 17.7 % 30 15.9 % 0.638
… thereby injured 17 54.8 % 15 50.0 % 0.705
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preferred way of medication supply), cultural and socio-
economic factors. Thus, the results of the present study
are likely to be highly generalisable. Third, patients’
adherence was measured using several validated instru-
ments providing internal validity. Fourth, the in-depth
telephone interviews on patient’s acceptance and know-
ledge were performed by trained independent clinical
psychologists, blinded to the intervention. Fifth, pa-
tients’ written self-reports were blinded to the pharma-
cists; thus a Pygmalion effect could be excluded.
Limitations
First, due to restricted financial means, the study period to
investigate the objective adherence was limited to just
28 weeks. With regard to the common package size of 100
tablets for long-term medication, the short study duration
offered only two refills to be considered for evaluation of
adherence. Newer guidelines suggest follow-up periods of
1–2 years or more to capture long term non-adherence
[55]. Second, patients enrolled in clinical trials may be
more conscientious than the average patient. During the
consent process, patients were told that the purpose of
the study was to learn more about their daily medicines
use and that their adherence to medication was observed.
Thus, all our patients knew they were being monitored,
which on the one hand may have led to a higher baseline
in self-reported adherence at study start and also during
follow-up in both groups of our study patients compared
to other patients. The pharmacists on the other hand
knew that they were being studied, which may have led
them to increase their efforts in delivering pharmaceutical
care, notably for both groups. This is known as the
Hawthorne effect: a psychological response in which sub-
jects in a research study change their behaviour simply be-
cause they are subjects in a study, not because of the
research treatment [56]. Thus, the heightened awareness
of the patients and also of the pharmacists about the study
setting could have influenced the medicines intake for the
prospective time. Such influence can only be eliminated
through a randomisation at the level of the pharmacy – a
procedure posing other problems of bias as well. In order
to avoid selection bias by the pharmacists, patients were
selected at random solely fulfilling the PMC-criteria and
not because of an increased risk or any indicators for
manifest non-adherence. Third, because of time constraints
and limited resources the recruitment was stopped before
the intended number of patients was recruited.
Implications for practice
In line with other authors [9, 55], we recommend to
ensure efficiency and efficacy to reconsider and adapt the
service on various levels: First, the service should be more
tailored to patients at higher risk for drug-related prob-
lems, such as patients with respiratory diseases, diagnosed
cardiovascular disease, regularly being prescribed at least
four medicines etc. In addition, focusing on patients
recently discharged from hospital, or who had changes in
their medicines regimen would provide more opportun-
ities to screen for manifest DRPs possibly before the start
of a risky treatment. Ideally, these patients would receive a
medication review within a very short time (e.g. a few
days) after the start and are followed by a follow-up meet-
ing (face-to-face or by telephone call) to check for hand-
ling issues and implementations of the recommendations.
Second, after detecting the patient at risk for clinical rele-
vant drug-related problems, we recommend to proceed
with validated, structured and standardised interventions.
This process should allow a follow-up to ensure imple-
mentation of pharmacists recommendations (according to
the pharmaceutical care process, see also the New Medi-
cines Service from the NHS, UK) [57]. The PMC protocol
form should include the documentation of the recommen-
dations or follow-up interventions in a more specific
structure. Thus, the current process of the PMC as a
service and its protocol need to be re-engineered. Third,
pharmacists had no training and supervision when provid-
ing the service. An implementation program focusing on
the main barriers of the service could still encourage
pharmacists to provide PMC in the future. A responsible
professional body for coaching and answering frequently
asked questions is needed. Qualification and/or accredit-
ation of involved health care providers might be consid-
ered to ensure high quality and safe interventions on
patient level. Continuing education should be strength-
ened through systematic integration of PMC cases into
practice-oriented teaching. For distinct problems or care
issues structured guidance should be developed.
Conclusion
For the first time in the Swiss health care system, a
newly implemented cognitive service of community
pharmacists underwent an in-depth evaluation process
in daily life. The service showed no significant improve-
ment on objective adherence in the observed population.
Reasons for not being able to demonstrate significant
positive effects are likely to depend on a) an uninten-
tional selection of patients with very high adherence and
low risk for drug-related problems causing insufficient
power and b) on a low level of experience with providing
the PMC among the recruited pharmacists.
However, based on the study results, we conclude that
the so called Polymedication Check as a pharmacist-led
medication review i) was able to address a significant
number of drug-related problems concerning adherence
issues and need for knowledge improvement and ii)
showed no further financial burden to the Swiss health
care system as there was no harm induced and pharma-
cists’ interventions did not cause additional consultations
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with other healthcare professionals. Re-engineering of the
service should focus on the inclusion criteria to target the
patients with highest risk for non-adherence and on the
improvement of pharmacists’ skills in implementing
weekly dosing aids.
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